Evidence map›Paper›PMID 38566821›Full record

ArticleUrology case reports2024

Tislelizumab combined with sunitinib in the treatment of metastatic clear cell renal cell carcinoma with renal venous tumor thrombus: A case report and literature review.

Zhixiang Gao, Lu Jin, Haijun Lv, Nengliang Duan, Guoneng Zhang, Yuanshuai Ran, Boxin Xue, Xiaolong Liu

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Urology case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Zhixiang GaoDepartment of Urology, Zhangjiagang Hospital Affiliated to Soochow University, China.
Lu JinDepartment of Urology, The Second Affiliated Hospital of Soochow University, China.
Haijun LvDepartment of Pathology, The Second Affiliated Hospital of Soochow University, China.
Nengliang DuanDepartment of Urology, The Second Affiliated Hospital of Soochow University, China.
Guoneng ZhangDepartment of Urology, The Second Affiliated Hospital of Soochow University, China.
Yuanshuai RanDepartment of Urology, The Second Affiliated Hospital of Soochow University, China.
Boxin XueDepartment of Urology, The Second Affiliated Hospital of Soochow University, China.
Xiaolong LiuDepartment of Urology, The Second Affiliated Hospital of Soochow University, China.
Second Affiliated Hospital of Soochow University · CNSoochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, with the in-depth study of PD-1/PD-L1 related pathways, great progress has been made in cancer immunotherapy. However, the immunotherapy regimen for mccRCC is still controversial in clinical practice. A 50-year-old man with mccRCC complicated with renal venous tumor thrombus from 2019 to present, including surgical treatment, targeted therapy and the combined treatment regimen of "Tislelizumab combined with Sunitinib". Although he experienced a roller coaster of adverse reactions during treatment, the patient's prognosis was good. Tislelizumab combined with Sunitinib is safe and effective in the Treatment of mccRCC.

Indexed as

ImmunotherapymccRCCTargeted therapyTislelizumab

Identifiers

PMID38566821
PMCPMC10986039
OpenAlexW4393281873

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.